Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 315 participants.

Also called NCT01619059

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 315 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01619059
  • EudraCT 2011-006323-37
Other papers using this trial's data
  • Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes Diabetes care, 2015-11 DOI, PubMed 26324329

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Hungary, Mexico, Poland, Puerto Rico, Romania, Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01619059. Randomized; triple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2014-06 (actual). Results posted on 2016-03-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes
Intervention (Drug)
Saxagliptin
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Metformin IR
Intervention (Drug)
Placebo matching with Saxagliptin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01619059
Content hash
c201179bb3ac98d704887fe77cadaf1511c33ac7f58cf4f23c6e5e873cc4a077